Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CASP1 | P29466 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12506154 | 0.98 | ALDH1A1 (0.56) | ALDH1A1MEN1CASP1KMT2ACASP7 | |
| SCHEMBL28547337 | 0.86 | ALDH1A1 (0.51) | ALDH1A1MEN1CASP1KMT2ACASP7 | |
| SCHEMBL360458 | 0.85 | NPC1 (0.57) | ALDH1A1MEN1CASP1KMT2ACASP7 | |
| SCHEMBL29952779 | 0.85 | NPC1 (0.57) | ALDH1A1MEN1CASP1KMT2ACASP7 | |
| Water SCHEMBL29954172 | 0.83 | NPC1 (0.55) | ALDH1A1MEN1CASP1KMT2ACASP7 | |
| Hydrochloric Acid SCHEMBL29952307 | 0.83 | NPC1 (0.55) | ALDH1A1MEN1CASP1KMT2ACASP7 | |
| SCHEMBL12488527 | 0.80 | NPC1 (0.52) | ALDH1A1MEN1CASP1KMT2ACASP7 | |
| SCHEMBL29420006 | 0.78 | CYP3A4 (0.56) | ALDH1A1MEN1CASP1KMT2ACASP7 | |
| SCHEMBL28715752 | 0.78 | CYP3A4 (0.56) | ALDH1A1MEN1CASP1KMT2ACASP7 | |
| SCHEMBL856485 | 0.75 | ENPP2 (0.55) | ALDH1A1MEN1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4703357-A1 | TRIAZOLYL-CONTAINING COMPOUNDS | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-12492168-B2 | Organic material for an electronic optoelectronic device and electronic device comprising the organic material | NOVALED GMBH (DE) | 2025-12-09 | — | — | US | disclosed |
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | CEPHALON LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| WO-2025111513-A1 | COMPOUNDS USEFUL IN THE MODULATION OF KLHDC1 AND KLHDC2 ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-114057815-B | Novel 6-6 bicyclic aromatic ring substituted nucleosides as PRMT5 inhibitors | 詹森药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20250002472-A1 | PYRIDYL-CONTAINING COMPOUND | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-01-02 | — | — | US | disclosed |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-02 | — | — | US | disclosed |
| WO-2024222900-A1 | TRIAZOLYL-CONTAINING COMPOUNDS | 正大天晴药业集团股份有限公司 | 2024-10-31 | — | — | WO | disclosed |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2024-09-24 | — | — | US | disclosed |
| US-7314933-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-01-01 | — | — | US | disclosed |
| EP-1807418-A2 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES AS VANILLOID RECEPTOR LIGANDS AND THEIR USES AS MEDICAMENT | Amgen, Inc (US) | 2007-07-18 | — | — | EP | disclosed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109354-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| WO-2006047492-A2 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES AS VANILLOID RECEPTOR LIGANDS AND THEIR USES AS MEDICAMENT | AMGEN INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060089360-A1 | Inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis; 6-(1H-indol-5-yl)-N-(4-(trifluoromethyl)phenyl)-4-pyrimidinamine | AMGEN INC. | 2006-04-27 | — | — | US | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1549634-A1 | NOVEL SUBSTITUTED INDOLES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2003101981-A1 | NOVEL SUBSTITUTED INDOLES | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | ALDH1A1 110/4885MEN1 3857/4885CASP1 816/4885 |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | ALDH1A1 3674/4885MEN1 1309/4885CASP1 803/4885 |
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | ALDH1A1 106/4885MEN1 4260/4885CASP1 831/4885 |
| US-12492168-B2 | Organic material for an electronic optoelectronic device and electronic device comprising the organic material | OCIAD1, OCIAD2, OR10J3 | ALDH1A1 574/4885MEN1 3903/4885CASP1 2937/4885 |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | HRH2, HRH1, HCAR2 | ALDH1A1 533/4885MEN1 4579/4885CASP1 3620/4885 |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | SSB, IDO1, IDO2 | ALDH1A1 2479/4885MEN1 2610/4885CASP1 845/4885 |
| US-20250002472-A1 | PYRIDYL-CONTAINING COMPOUND | DPYD, TYMP, WEE1 | ALDH1A1 594/4885MEN1 248/4885CASP1 231/4885 |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | ALDH1A1 110/4885MEN1 3857/4885CASP1 816/4885 |
| US-20060089360-A1 | Inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis; 6-(1H-indol-5-yl)-N-(4-(trifluoromethyl)phenyl)-4-pyrimidinamine | TRPV1, TRPA1, TRPV3 | ALDH1A1 1866/4885MEN1 3420/4885CASP1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.